BIOSIMILARS NEDERLAND

Educational Meeting on Biosimilar Monoclonal Antibodies

Amsterdam, 3 september 2015

Summary/Take home messages

BIOSIMILARS NEDERLAND

Summary/Take home messages

- Biosimilars are similar to the reference product (Giezen)
- We can rely on the progress made in regulatory science over 20 years to come to a consistent, fair, and science-based conclusion of biosimilarity. (Goncalves)
- No reason to assume that switching to/from biosimilars will lead to safety problems. (Ebbers)

BIOSIMILARS NEDERLAND

Take home messages from Norway

- LIS agreements allowing us to treat more patients Utne Sørensen, revmatologisk dep. Haukeland Hospital (Aanes)
- Key success factors:
- - Seminars with an academic approach, information regarding consumption and recommendations for use
- - Recommendations from the specialist groups provide clinical acceptance (Aanes)
- More HTA, More tenders (Mack)

BIOSIMILARS NEDERLAND

Take home messages for the Netherlands

- Biosimilars: huge potential for savings in health care expenditure (Koopmanschap)
- Limited resistence against biosimilar use in new patients; (d'Haens)
- Switching is possible, but only if adequate clinical monitoring is performed and the patient is well informed. (Franken)
- Tracebility: ….carefully register product name and batch number in the patient file to assure traceability in case unexpected findings occur. (Tjoeng)

BIOSIMILARS NEDERLAND

Initiative group Biosimilars the Netherlands

- Affordable care with uncompromised quality and safety
- Guaranteed access to treatment for all patients
- Sustainable drug provision including innovation (adequate price level for generics and biosimilars, so they can survive)

- www.biosimilar-nederland.nl
- LinkedIn: Biosimilar-Nederland
- Twitter: @BiosimilarNL

BIOSIMILARS NEDERLAND

Thanks

- The speakers
- The chair and co-chairs
- The congress organisers
- All the participants

BIOSIMILARS NEDERLAND

BIOSIMILARS NEDERLAND

Educational Meeting on Biosimilar Monoclonal Antibodies

Amsterdam, 3 september 2015